Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions
Low-dose-rate brachytherapy (LDR-BT) in localized prostate cancer is available since 15 years in Italy. We realized the first national multicentre and multidisciplinary data collection to evaluate LDR-BT practice, given as monotherapy, and outcome in terms of biochemical failure. Between May 1998 an...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Fellin, Giovanni [verfasserIn] |
|---|
| Format: |
Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016 |
|---|
| Systematik: |
|
|---|
| Übergeordnetes Werk: |
Enthalten in: The British journal of radiology - Oxford : Oxford University Press, 1928, 89(2016), 1065 |
|---|---|
| Übergeordnetes Werk: |
volume:89 ; year:2016 ; number:1065 |
| Links: |
|---|
| DOI / URN: |
10.1259/bjr.20150981 |
|---|
| Katalog-ID: |
OLC1981412697 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1981412697 | ||
| 003 | DE-627 | ||
| 005 | 20230509072502.0 | ||
| 007 | tu | ||
| 008 | 161013s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1259/bjr.20150981 |2 doi | |
| 028 | 5 | 2 | |a PQ20161012 |
| 035 | |a (DE-627)OLC1981412697 | ||
| 035 | |a (DE-599)GBVOLC1981412697 | ||
| 035 | |a (PRQ)c1252-84ec96a94320e494dbafe52275f7b82e289e807aec42a24440a05a08ad580d830 | ||
| 035 | |a (KEY)0026188220160000089106500000lowdoseratebrachytherapyldrbtasmonotherapyforearly | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a XA 34700 |q AVZ |2 rvk | ||
| 084 | |a 44.64 |2 bkl | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Fellin, Giovanni |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Low-dose-rate brachytherapy (LDR-BT) in localized prostate cancer is available since 15 years in Italy. We realized the first national multicentre and multidisciplinary data collection to evaluate LDR-BT practice, given as monotherapy, and outcome in terms of biochemical failure. Between May 1998 and December 2011, 2237 patients with early-stage prostate cancer from 11 Italian community and academic hospitals were treated with iodine-125 ((125)I) or palladium-103 LDR-BT as monotherapy and followed up for at least 2 years. (125)I seeds were implanted in 97.7% of the patients: the mean dose received by 90% of target volume was 145 Gy; the mean target volume receiving 100% of prescribed dose (V100) was 91.1%. Biochemical failure-free survival (BFFS), disease-specific survival (DSS) and overall survival (OS) were estimated using Kaplan-Meier method. Log-rank test and multivariable Cox regression were used to evaluate the relationship of covariates with outcomes. Median follow-up time was 65 months. 5- and 7-year DSS, OS and BFFS were 99 and 98%, 94 and 89%, and 92 and 88%, respectively. At multivariate analysis, the National Comprehensive Cancer Network score (p < 0.0001) and V100 (p = 0.09) were correlated with BFFS, with V100 effect significantly different between patients at low risk and those at intermediate/high risk (p = 0.04). Short follow-up and lack of toxicity data represent the main limitations for a global evaluation of LDR-BT. This first multicentre Italian report confirms LDR-BT as an excellent curative modality for low-/intermediate-risk prostate cancer. Multidisciplinary teams may help to select adequately patients to be treated with brachytherapy, with a direct impact on the implant quality and, possibly, on outcome. | ||
| 700 | 1 | |a Mirri, Maria A |4 oth | |
| 700 | 1 | |a Santoro, Luigi |4 oth | |
| 700 | 1 | |a Jereczek-Fossa, Barbara A |4 oth | |
| 700 | 1 | |a Divan, Claudio |4 oth | |
| 700 | 1 | |a Mussari, Salvatore |4 oth | |
| 700 | 1 | |a Ziglio, Francesco |4 oth | |
| 700 | 1 | |a La Face, Beniamino |4 oth | |
| 700 | 1 | |a Barbera, Fernando |4 oth | |
| 700 | 1 | |a Buglione, Michela |4 oth | |
| 700 | 1 | |a Bandera, Laura |4 oth | |
| 700 | 1 | |a Ghedi, Barbara |4 oth | |
| 700 | 1 | |a Di Muzio, Nadia G |4 oth | |
| 700 | 1 | |a Losa, Andrea |4 oth | |
| 700 | 1 | |a Mangili, Paola |4 oth | |
| 700 | 1 | |a Nava, Luciano |4 oth | |
| 700 | 1 | |a Chiarlone, Renato |4 oth | |
| 700 | 1 | |a Ciscognetti, Nunzia |4 oth | |
| 700 | 1 | |a Gastaldi, Emilio |4 oth | |
| 700 | 1 | |a Cattani, Federica |4 oth | |
| 700 | 1 | |a Spoto, Ruggero |4 oth | |
| 700 | 1 | |a Vavassori, Andrea |4 oth | |
| 700 | 1 | |a Giglioli, Francesca R |4 oth | |
| 700 | 1 | |a Guarneri, Alessia |4 oth | |
| 700 | 1 | |a Cerboneschi, Valentina |4 oth | |
| 700 | 1 | |a Mignogna, Marcello |4 oth | |
| 700 | 1 | |a Paoluzzi, Mauro |4 oth | |
| 700 | 1 | |a Ravaglia, Valentina |4 oth | |
| 700 | 1 | |a Chiumento, Costanza |4 oth | |
| 700 | 1 | |a Clemente, Stefania |4 oth | |
| 700 | 1 | |a Fusco, Vincenzo |4 oth | |
| 700 | 1 | |a Santini, Roberto |4 oth | |
| 700 | 1 | |a Stefanacci, Marco |4 oth | |
| 700 | 1 | |a Mangiacotti, Francesco P |4 oth | |
| 700 | 1 | |a Martini, Marco |4 oth | |
| 700 | 1 | |a Palloni, Tiziana |4 oth | |
| 700 | 1 | |a Schinaia, Giuseppe |4 oth | |
| 700 | 1 | |a Lazzari, Grazia |4 oth | |
| 700 | 1 | |a Silvano, Giovanni |4 oth | |
| 700 | 1 | |a Magrini, Stefano |4 oth | |
| 700 | 1 | |a Ricardi, Umberto |4 oth | |
| 700 | 1 | |a Santoni, Riccardo |4 oth | |
| 700 | 1 | |a Orecchia, Roberto |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The British journal of radiology |d Oxford : Oxford University Press, 1928 |g 89(2016), 1065 |w (DE-627)129077976 |w (DE-600)2982-8 |w (DE-576)014410524 |x 0007-1285 |7 nnns |
| 773 | 1 | 8 | |g volume:89 |g year:2016 |g number:1065 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1259/bjr.20150981 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/27384381 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHY | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4305 | ||
| 936 | r | v | |a XA 34700 |
| 936 | b | k | |a 44.64 |q AVZ |
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 89 |j 2016 |e 1065 | ||
| author_variant |
g f gf |
|---|---|
| matchkey_str |
article:00071285:2016----::odsrtbahteaydbamnteayoerytgpottcneiiayrcienotoenlssn |
| hierarchy_sort_str |
2016 |
| bklnumber |
44.64 44.40 |
| publishDate |
2016 |
| allfields |
10.1259/bjr.20150981 doi PQ20161012 (DE-627)OLC1981412697 (DE-599)GBVOLC1981412697 (PRQ)c1252-84ec96a94320e494dbafe52275f7b82e289e807aec42a24440a05a08ad580d830 (KEY)0026188220160000089106500000lowdoseratebrachytherapyldrbtasmonotherapyforearly DE-627 ger DE-627 rakwb eng 610 DNB XA 34700 AVZ rvk 44.64 bkl 44.40 bkl Fellin, Giovanni verfasserin aut Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions 2016 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier Low-dose-rate brachytherapy (LDR-BT) in localized prostate cancer is available since 15 years in Italy. We realized the first national multicentre and multidisciplinary data collection to evaluate LDR-BT practice, given as monotherapy, and outcome in terms of biochemical failure. Between May 1998 and December 2011, 2237 patients with early-stage prostate cancer from 11 Italian community and academic hospitals were treated with iodine-125 ((125)I) or palladium-103 LDR-BT as monotherapy and followed up for at least 2 years. (125)I seeds were implanted in 97.7% of the patients: the mean dose received by 90% of target volume was 145 Gy; the mean target volume receiving 100% of prescribed dose (V100) was 91.1%. Biochemical failure-free survival (BFFS), disease-specific survival (DSS) and overall survival (OS) were estimated using Kaplan-Meier method. Log-rank test and multivariable Cox regression were used to evaluate the relationship of covariates with outcomes. Median follow-up time was 65 months. 5- and 7-year DSS, OS and BFFS were 99 and 98%, 94 and 89%, and 92 and 88%, respectively. At multivariate analysis, the National Comprehensive Cancer Network score (p < 0.0001) and V100 (p = 0.09) were correlated with BFFS, with V100 effect significantly different between patients at low risk and those at intermediate/high risk (p = 0.04). Short follow-up and lack of toxicity data represent the main limitations for a global evaluation of LDR-BT. This first multicentre Italian report confirms LDR-BT as an excellent curative modality for low-/intermediate-risk prostate cancer. Multidisciplinary teams may help to select adequately patients to be treated with brachytherapy, with a direct impact on the implant quality and, possibly, on outcome. Mirri, Maria A oth Santoro, Luigi oth Jereczek-Fossa, Barbara A oth Divan, Claudio oth Mussari, Salvatore oth Ziglio, Francesco oth La Face, Beniamino oth Barbera, Fernando oth Buglione, Michela oth Bandera, Laura oth Ghedi, Barbara oth Di Muzio, Nadia G oth Losa, Andrea oth Mangili, Paola oth Nava, Luciano oth Chiarlone, Renato oth Ciscognetti, Nunzia oth Gastaldi, Emilio oth Cattani, Federica oth Spoto, Ruggero oth Vavassori, Andrea oth Giglioli, Francesca R oth Guarneri, Alessia oth Cerboneschi, Valentina oth Mignogna, Marcello oth Paoluzzi, Mauro oth Ravaglia, Valentina oth Chiumento, Costanza oth Clemente, Stefania oth Fusco, Vincenzo oth Santini, Roberto oth Stefanacci, Marco oth Mangiacotti, Francesco P oth Martini, Marco oth Palloni, Tiziana oth Schinaia, Giuseppe oth Lazzari, Grazia oth Silvano, Giovanni oth Magrini, Stefano oth Ricardi, Umberto oth Santoni, Riccardo oth Orecchia, Roberto oth Enthalten in The British journal of radiology Oxford : Oxford University Press, 1928 89(2016), 1065 (DE-627)129077976 (DE-600)2982-8 (DE-576)014410524 0007-1285 nnns volume:89 year:2016 number:1065 http://dx.doi.org/10.1259/bjr.20150981 Volltext http://www.ncbi.nlm.nih.gov/pubmed/27384381 GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-PHY SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_24 GBV_ILN_170 GBV_ILN_4012 GBV_ILN_4219 GBV_ILN_4305 XA 34700 44.64 AVZ 44.40 AVZ AR 89 2016 1065 |
| spelling |
10.1259/bjr.20150981 doi PQ20161012 (DE-627)OLC1981412697 (DE-599)GBVOLC1981412697 (PRQ)c1252-84ec96a94320e494dbafe52275f7b82e289e807aec42a24440a05a08ad580d830 (KEY)0026188220160000089106500000lowdoseratebrachytherapyldrbtasmonotherapyforearly DE-627 ger DE-627 rakwb eng 610 DNB XA 34700 AVZ rvk 44.64 bkl 44.40 bkl Fellin, Giovanni verfasserin aut Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions 2016 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier Low-dose-rate brachytherapy (LDR-BT) in localized prostate cancer is available since 15 years in Italy. We realized the first national multicentre and multidisciplinary data collection to evaluate LDR-BT practice, given as monotherapy, and outcome in terms of biochemical failure. Between May 1998 and December 2011, 2237 patients with early-stage prostate cancer from 11 Italian community and academic hospitals were treated with iodine-125 ((125)I) or palladium-103 LDR-BT as monotherapy and followed up for at least 2 years. (125)I seeds were implanted in 97.7% of the patients: the mean dose received by 90% of target volume was 145 Gy; the mean target volume receiving 100% of prescribed dose (V100) was 91.1%. Biochemical failure-free survival (BFFS), disease-specific survival (DSS) and overall survival (OS) were estimated using Kaplan-Meier method. Log-rank test and multivariable Cox regression were used to evaluate the relationship of covariates with outcomes. Median follow-up time was 65 months. 5- and 7-year DSS, OS and BFFS were 99 and 98%, 94 and 89%, and 92 and 88%, respectively. At multivariate analysis, the National Comprehensive Cancer Network score (p < 0.0001) and V100 (p = 0.09) were correlated with BFFS, with V100 effect significantly different between patients at low risk and those at intermediate/high risk (p = 0.04). Short follow-up and lack of toxicity data represent the main limitations for a global evaluation of LDR-BT. This first multicentre Italian report confirms LDR-BT as an excellent curative modality for low-/intermediate-risk prostate cancer. Multidisciplinary teams may help to select adequately patients to be treated with brachytherapy, with a direct impact on the implant quality and, possibly, on outcome. Mirri, Maria A oth Santoro, Luigi oth Jereczek-Fossa, Barbara A oth Divan, Claudio oth Mussari, Salvatore oth Ziglio, Francesco oth La Face, Beniamino oth Barbera, Fernando oth Buglione, Michela oth Bandera, Laura oth Ghedi, Barbara oth Di Muzio, Nadia G oth Losa, Andrea oth Mangili, Paola oth Nava, Luciano oth Chiarlone, Renato oth Ciscognetti, Nunzia oth Gastaldi, Emilio oth Cattani, Federica oth Spoto, Ruggero oth Vavassori, Andrea oth Giglioli, Francesca R oth Guarneri, Alessia oth Cerboneschi, Valentina oth Mignogna, Marcello oth Paoluzzi, Mauro oth Ravaglia, Valentina oth Chiumento, Costanza oth Clemente, Stefania oth Fusco, Vincenzo oth Santini, Roberto oth Stefanacci, Marco oth Mangiacotti, Francesco P oth Martini, Marco oth Palloni, Tiziana oth Schinaia, Giuseppe oth Lazzari, Grazia oth Silvano, Giovanni oth Magrini, Stefano oth Ricardi, Umberto oth Santoni, Riccardo oth Orecchia, Roberto oth Enthalten in The British journal of radiology Oxford : Oxford University Press, 1928 89(2016), 1065 (DE-627)129077976 (DE-600)2982-8 (DE-576)014410524 0007-1285 nnns volume:89 year:2016 number:1065 http://dx.doi.org/10.1259/bjr.20150981 Volltext http://www.ncbi.nlm.nih.gov/pubmed/27384381 GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-PHY SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_24 GBV_ILN_170 GBV_ILN_4012 GBV_ILN_4219 GBV_ILN_4305 XA 34700 44.64 AVZ 44.40 AVZ AR 89 2016 1065 |
| allfields_unstemmed |
10.1259/bjr.20150981 doi PQ20161012 (DE-627)OLC1981412697 (DE-599)GBVOLC1981412697 (PRQ)c1252-84ec96a94320e494dbafe52275f7b82e289e807aec42a24440a05a08ad580d830 (KEY)0026188220160000089106500000lowdoseratebrachytherapyldrbtasmonotherapyforearly DE-627 ger DE-627 rakwb eng 610 DNB XA 34700 AVZ rvk 44.64 bkl 44.40 bkl Fellin, Giovanni verfasserin aut Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions 2016 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier Low-dose-rate brachytherapy (LDR-BT) in localized prostate cancer is available since 15 years in Italy. We realized the first national multicentre and multidisciplinary data collection to evaluate LDR-BT practice, given as monotherapy, and outcome in terms of biochemical failure. Between May 1998 and December 2011, 2237 patients with early-stage prostate cancer from 11 Italian community and academic hospitals were treated with iodine-125 ((125)I) or palladium-103 LDR-BT as monotherapy and followed up for at least 2 years. (125)I seeds were implanted in 97.7% of the patients: the mean dose received by 90% of target volume was 145 Gy; the mean target volume receiving 100% of prescribed dose (V100) was 91.1%. Biochemical failure-free survival (BFFS), disease-specific survival (DSS) and overall survival (OS) were estimated using Kaplan-Meier method. Log-rank test and multivariable Cox regression were used to evaluate the relationship of covariates with outcomes. Median follow-up time was 65 months. 5- and 7-year DSS, OS and BFFS were 99 and 98%, 94 and 89%, and 92 and 88%, respectively. At multivariate analysis, the National Comprehensive Cancer Network score (p < 0.0001) and V100 (p = 0.09) were correlated with BFFS, with V100 effect significantly different between patients at low risk and those at intermediate/high risk (p = 0.04). Short follow-up and lack of toxicity data represent the main limitations for a global evaluation of LDR-BT. This first multicentre Italian report confirms LDR-BT as an excellent curative modality for low-/intermediate-risk prostate cancer. Multidisciplinary teams may help to select adequately patients to be treated with brachytherapy, with a direct impact on the implant quality and, possibly, on outcome. Mirri, Maria A oth Santoro, Luigi oth Jereczek-Fossa, Barbara A oth Divan, Claudio oth Mussari, Salvatore oth Ziglio, Francesco oth La Face, Beniamino oth Barbera, Fernando oth Buglione, Michela oth Bandera, Laura oth Ghedi, Barbara oth Di Muzio, Nadia G oth Losa, Andrea oth Mangili, Paola oth Nava, Luciano oth Chiarlone, Renato oth Ciscognetti, Nunzia oth Gastaldi, Emilio oth Cattani, Federica oth Spoto, Ruggero oth Vavassori, Andrea oth Giglioli, Francesca R oth Guarneri, Alessia oth Cerboneschi, Valentina oth Mignogna, Marcello oth Paoluzzi, Mauro oth Ravaglia, Valentina oth Chiumento, Costanza oth Clemente, Stefania oth Fusco, Vincenzo oth Santini, Roberto oth Stefanacci, Marco oth Mangiacotti, Francesco P oth Martini, Marco oth Palloni, Tiziana oth Schinaia, Giuseppe oth Lazzari, Grazia oth Silvano, Giovanni oth Magrini, Stefano oth Ricardi, Umberto oth Santoni, Riccardo oth Orecchia, Roberto oth Enthalten in The British journal of radiology Oxford : Oxford University Press, 1928 89(2016), 1065 (DE-627)129077976 (DE-600)2982-8 (DE-576)014410524 0007-1285 nnns volume:89 year:2016 number:1065 http://dx.doi.org/10.1259/bjr.20150981 Volltext http://www.ncbi.nlm.nih.gov/pubmed/27384381 GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-PHY SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_24 GBV_ILN_170 GBV_ILN_4012 GBV_ILN_4219 GBV_ILN_4305 XA 34700 44.64 AVZ 44.40 AVZ AR 89 2016 1065 |
| allfieldsGer |
10.1259/bjr.20150981 doi PQ20161012 (DE-627)OLC1981412697 (DE-599)GBVOLC1981412697 (PRQ)c1252-84ec96a94320e494dbafe52275f7b82e289e807aec42a24440a05a08ad580d830 (KEY)0026188220160000089106500000lowdoseratebrachytherapyldrbtasmonotherapyforearly DE-627 ger DE-627 rakwb eng 610 DNB XA 34700 AVZ rvk 44.64 bkl 44.40 bkl Fellin, Giovanni verfasserin aut Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions 2016 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier Low-dose-rate brachytherapy (LDR-BT) in localized prostate cancer is available since 15 years in Italy. We realized the first national multicentre and multidisciplinary data collection to evaluate LDR-BT practice, given as monotherapy, and outcome in terms of biochemical failure. Between May 1998 and December 2011, 2237 patients with early-stage prostate cancer from 11 Italian community and academic hospitals were treated with iodine-125 ((125)I) or palladium-103 LDR-BT as monotherapy and followed up for at least 2 years. (125)I seeds were implanted in 97.7% of the patients: the mean dose received by 90% of target volume was 145 Gy; the mean target volume receiving 100% of prescribed dose (V100) was 91.1%. Biochemical failure-free survival (BFFS), disease-specific survival (DSS) and overall survival (OS) were estimated using Kaplan-Meier method. Log-rank test and multivariable Cox regression were used to evaluate the relationship of covariates with outcomes. Median follow-up time was 65 months. 5- and 7-year DSS, OS and BFFS were 99 and 98%, 94 and 89%, and 92 and 88%, respectively. At multivariate analysis, the National Comprehensive Cancer Network score (p < 0.0001) and V100 (p = 0.09) were correlated with BFFS, with V100 effect significantly different between patients at low risk and those at intermediate/high risk (p = 0.04). Short follow-up and lack of toxicity data represent the main limitations for a global evaluation of LDR-BT. This first multicentre Italian report confirms LDR-BT as an excellent curative modality for low-/intermediate-risk prostate cancer. Multidisciplinary teams may help to select adequately patients to be treated with brachytherapy, with a direct impact on the implant quality and, possibly, on outcome. Mirri, Maria A oth Santoro, Luigi oth Jereczek-Fossa, Barbara A oth Divan, Claudio oth Mussari, Salvatore oth Ziglio, Francesco oth La Face, Beniamino oth Barbera, Fernando oth Buglione, Michela oth Bandera, Laura oth Ghedi, Barbara oth Di Muzio, Nadia G oth Losa, Andrea oth Mangili, Paola oth Nava, Luciano oth Chiarlone, Renato oth Ciscognetti, Nunzia oth Gastaldi, Emilio oth Cattani, Federica oth Spoto, Ruggero oth Vavassori, Andrea oth Giglioli, Francesca R oth Guarneri, Alessia oth Cerboneschi, Valentina oth Mignogna, Marcello oth Paoluzzi, Mauro oth Ravaglia, Valentina oth Chiumento, Costanza oth Clemente, Stefania oth Fusco, Vincenzo oth Santini, Roberto oth Stefanacci, Marco oth Mangiacotti, Francesco P oth Martini, Marco oth Palloni, Tiziana oth Schinaia, Giuseppe oth Lazzari, Grazia oth Silvano, Giovanni oth Magrini, Stefano oth Ricardi, Umberto oth Santoni, Riccardo oth Orecchia, Roberto oth Enthalten in The British journal of radiology Oxford : Oxford University Press, 1928 89(2016), 1065 (DE-627)129077976 (DE-600)2982-8 (DE-576)014410524 0007-1285 nnns volume:89 year:2016 number:1065 http://dx.doi.org/10.1259/bjr.20150981 Volltext http://www.ncbi.nlm.nih.gov/pubmed/27384381 GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-PHY SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_24 GBV_ILN_170 GBV_ILN_4012 GBV_ILN_4219 GBV_ILN_4305 XA 34700 44.64 AVZ 44.40 AVZ AR 89 2016 1065 |
| allfieldsSound |
10.1259/bjr.20150981 doi PQ20161012 (DE-627)OLC1981412697 (DE-599)GBVOLC1981412697 (PRQ)c1252-84ec96a94320e494dbafe52275f7b82e289e807aec42a24440a05a08ad580d830 (KEY)0026188220160000089106500000lowdoseratebrachytherapyldrbtasmonotherapyforearly DE-627 ger DE-627 rakwb eng 610 DNB XA 34700 AVZ rvk 44.64 bkl 44.40 bkl Fellin, Giovanni verfasserin aut Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions 2016 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier Low-dose-rate brachytherapy (LDR-BT) in localized prostate cancer is available since 15 years in Italy. We realized the first national multicentre and multidisciplinary data collection to evaluate LDR-BT practice, given as monotherapy, and outcome in terms of biochemical failure. Between May 1998 and December 2011, 2237 patients with early-stage prostate cancer from 11 Italian community and academic hospitals were treated with iodine-125 ((125)I) or palladium-103 LDR-BT as monotherapy and followed up for at least 2 years. (125)I seeds were implanted in 97.7% of the patients: the mean dose received by 90% of target volume was 145 Gy; the mean target volume receiving 100% of prescribed dose (V100) was 91.1%. Biochemical failure-free survival (BFFS), disease-specific survival (DSS) and overall survival (OS) were estimated using Kaplan-Meier method. Log-rank test and multivariable Cox regression were used to evaluate the relationship of covariates with outcomes. Median follow-up time was 65 months. 5- and 7-year DSS, OS and BFFS were 99 and 98%, 94 and 89%, and 92 and 88%, respectively. At multivariate analysis, the National Comprehensive Cancer Network score (p < 0.0001) and V100 (p = 0.09) were correlated with BFFS, with V100 effect significantly different between patients at low risk and those at intermediate/high risk (p = 0.04). Short follow-up and lack of toxicity data represent the main limitations for a global evaluation of LDR-BT. This first multicentre Italian report confirms LDR-BT as an excellent curative modality for low-/intermediate-risk prostate cancer. Multidisciplinary teams may help to select adequately patients to be treated with brachytherapy, with a direct impact on the implant quality and, possibly, on outcome. Mirri, Maria A oth Santoro, Luigi oth Jereczek-Fossa, Barbara A oth Divan, Claudio oth Mussari, Salvatore oth Ziglio, Francesco oth La Face, Beniamino oth Barbera, Fernando oth Buglione, Michela oth Bandera, Laura oth Ghedi, Barbara oth Di Muzio, Nadia G oth Losa, Andrea oth Mangili, Paola oth Nava, Luciano oth Chiarlone, Renato oth Ciscognetti, Nunzia oth Gastaldi, Emilio oth Cattani, Federica oth Spoto, Ruggero oth Vavassori, Andrea oth Giglioli, Francesca R oth Guarneri, Alessia oth Cerboneschi, Valentina oth Mignogna, Marcello oth Paoluzzi, Mauro oth Ravaglia, Valentina oth Chiumento, Costanza oth Clemente, Stefania oth Fusco, Vincenzo oth Santini, Roberto oth Stefanacci, Marco oth Mangiacotti, Francesco P oth Martini, Marco oth Palloni, Tiziana oth Schinaia, Giuseppe oth Lazzari, Grazia oth Silvano, Giovanni oth Magrini, Stefano oth Ricardi, Umberto oth Santoni, Riccardo oth Orecchia, Roberto oth Enthalten in The British journal of radiology Oxford : Oxford University Press, 1928 89(2016), 1065 (DE-627)129077976 (DE-600)2982-8 (DE-576)014410524 0007-1285 nnns volume:89 year:2016 number:1065 http://dx.doi.org/10.1259/bjr.20150981 Volltext http://www.ncbi.nlm.nih.gov/pubmed/27384381 GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-PHY SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_24 GBV_ILN_170 GBV_ILN_4012 GBV_ILN_4219 GBV_ILN_4305 XA 34700 44.64 AVZ 44.40 AVZ AR 89 2016 1065 |
| language |
English |
| source |
Enthalten in The British journal of radiology 89(2016), 1065 volume:89 year:2016 number:1065 |
| sourceStr |
Enthalten in The British journal of radiology 89(2016), 1065 volume:89 year:2016 number:1065 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
The British journal of radiology |
| authorswithroles_txt_mv |
Fellin, Giovanni @@aut@@ Mirri, Maria A @@oth@@ Santoro, Luigi @@oth@@ Jereczek-Fossa, Barbara A @@oth@@ Divan, Claudio @@oth@@ Mussari, Salvatore @@oth@@ Ziglio, Francesco @@oth@@ La Face, Beniamino @@oth@@ Barbera, Fernando @@oth@@ Buglione, Michela @@oth@@ Bandera, Laura @@oth@@ Ghedi, Barbara @@oth@@ Di Muzio, Nadia G @@oth@@ Losa, Andrea @@oth@@ Mangili, Paola @@oth@@ Nava, Luciano @@oth@@ Chiarlone, Renato @@oth@@ Ciscognetti, Nunzia @@oth@@ Gastaldi, Emilio @@oth@@ Cattani, Federica @@oth@@ Spoto, Ruggero @@oth@@ Vavassori, Andrea @@oth@@ Giglioli, Francesca R @@oth@@ Guarneri, Alessia @@oth@@ Cerboneschi, Valentina @@oth@@ Mignogna, Marcello @@oth@@ Paoluzzi, Mauro @@oth@@ Ravaglia, Valentina @@oth@@ Chiumento, Costanza @@oth@@ Clemente, Stefania @@oth@@ Fusco, Vincenzo @@oth@@ Santini, Roberto @@oth@@ Stefanacci, Marco @@oth@@ Mangiacotti, Francesco P @@oth@@ Martini, Marco @@oth@@ Palloni, Tiziana @@oth@@ Schinaia, Giuseppe @@oth@@ Lazzari, Grazia @@oth@@ Silvano, Giovanni @@oth@@ Magrini, Stefano @@oth@@ Ricardi, Umberto @@oth@@ Santoni, Riccardo @@oth@@ Orecchia, Roberto @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
129077976 |
| dewey-sort |
3610 |
| id |
OLC1981412697 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a2200265 4500</leader><controlfield tag="001">OLC1981412697</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230509072502.0</controlfield><controlfield tag="007">tu</controlfield><controlfield tag="008">161013s2016 xx ||||| 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1259/bjr.20150981</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">PQ20161012</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)OLC1981412697</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)GBVOLC1981412697</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(PRQ)c1252-84ec96a94320e494dbafe52275f7b82e289e807aec42a24440a05a08ad580d830</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(KEY)0026188220160000089106500000lowdoseratebrachytherapyldrbtasmonotherapyforearly</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DNB</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XA 34700</subfield><subfield code="q">AVZ</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.64</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Fellin, Giovanni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">ohne Hilfsmittel zu benutzen</subfield><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Band</subfield><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Low-dose-rate brachytherapy (LDR-BT) in localized prostate cancer is available since 15 years in Italy. We realized the first national multicentre and multidisciplinary data collection to evaluate LDR-BT practice, given as monotherapy, and outcome in terms of biochemical failure. Between May 1998 and December 2011, 2237 patients with early-stage prostate cancer from 11 Italian community and academic hospitals were treated with iodine-125 ((125)I) or palladium-103 LDR-BT as monotherapy and followed up for at least 2 years. (125)I seeds were implanted in 97.7% of the patients: the mean dose received by 90% of target volume was 145 Gy; the mean target volume receiving 100% of prescribed dose (V100) was 91.1%. Biochemical failure-free survival (BFFS), disease-specific survival (DSS) and overall survival (OS) were estimated using Kaplan-Meier method. Log-rank test and multivariable Cox regression were used to evaluate the relationship of covariates with outcomes. Median follow-up time was 65 months. 5- and 7-year DSS, OS and BFFS were 99 and 98%, 94 and 89%, and 92 and 88%, respectively. At multivariate analysis, the National Comprehensive Cancer Network score (p < 0.0001) and V100 (p = 0.09) were correlated with BFFS, with V100 effect significantly different between patients at low risk and those at intermediate/high risk (p = 0.04). Short follow-up and lack of toxicity data represent the main limitations for a global evaluation of LDR-BT. This first multicentre Italian report confirms LDR-BT as an excellent curative modality for low-/intermediate-risk prostate cancer. Multidisciplinary teams may help to select adequately patients to be treated with brachytherapy, with a direct impact on the implant quality and, possibly, on outcome.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mirri, Maria A</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Santoro, Luigi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jereczek-Fossa, Barbara A</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Divan, Claudio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mussari, Salvatore</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ziglio, Francesco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">La Face, Beniamino</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barbera, Fernando</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buglione, Michela</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bandera, Laura</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ghedi, Barbara</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Di Muzio, Nadia G</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Losa, Andrea</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mangili, Paola</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nava, Luciano</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chiarlone, Renato</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ciscognetti, Nunzia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gastaldi, Emilio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cattani, Federica</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Spoto, Ruggero</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vavassori, Andrea</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Giglioli, Francesca R</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guarneri, Alessia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cerboneschi, Valentina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mignogna, Marcello</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Paoluzzi, Mauro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ravaglia, Valentina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chiumento, Costanza</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Clemente, Stefania</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fusco, Vincenzo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Santini, Roberto</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stefanacci, Marco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mangiacotti, Francesco P</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Martini, Marco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Palloni, Tiziana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schinaia, Giuseppe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lazzari, Grazia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Silvano, Giovanni</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Magrini, Stefano</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ricardi, Umberto</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Santoni, Riccardo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Orecchia, Roberto</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The British journal of radiology</subfield><subfield code="d">Oxford : Oxford University Press, 1928</subfield><subfield code="g">89(2016), 1065</subfield><subfield code="w">(DE-627)129077976</subfield><subfield code="w">(DE-600)2982-8</subfield><subfield code="w">(DE-576)014410524</subfield><subfield code="x">0007-1285</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:89</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:1065</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">http://dx.doi.org/10.1259/bjr.20150981</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">http://www.ncbi.nlm.nih.gov/pubmed/27384381</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_OLC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-DE-84</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4219</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="936" ind1="r" ind2="v"><subfield code="a">XA 34700</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.64</subfield><subfield code="q">AVZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">AVZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">89</subfield><subfield code="j">2016</subfield><subfield code="e">1065</subfield></datafield></record></collection>
|
| author |
Fellin, Giovanni |
| spellingShingle |
Fellin, Giovanni ddc 610 rvk XA 34700 bkl 44.64 bkl 44.40 Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions |
| authorStr |
Fellin, Giovanni |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)129077976 |
| format |
Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
OLC |
| remote_str |
false |
| illustrated |
Not Illustrated |
| issn |
0007-1285 |
| topic_title |
610 DNB XA 34700 AVZ rvk 44.64 bkl 44.40 bkl Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions |
| topic |
ddc 610 rvk XA 34700 bkl 44.64 bkl 44.40 |
| topic_unstemmed |
ddc 610 rvk XA 34700 bkl 44.64 bkl 44.40 |
| topic_browse |
ddc 610 rvk XA 34700 bkl 44.64 bkl 44.40 |
| format_facet |
Aufsätze Gedruckte Aufsätze |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
nc |
| author2_variant |
m a m ma mam l s ls b a j f baj bajf c d cd s m sm f z fz f b l fb fbl f b fb m b mb l b lb b g bg m n g d mng mngd a l al p m pm l n ln r c rc n c nc e g eg f c fc r s rs a v av f r g fr frg a g ag v c vc m m mm m p mp v r vr c c cc s c sc v f vf r s rs m s ms f p m fp fpm m m mm t p tp g s gs g l gl g s gs s m sm u r ur r s rs r o ro |
| hierarchy_parent_title |
The British journal of radiology |
| hierarchy_parent_id |
129077976 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
The British journal of radiology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)129077976 (DE-600)2982-8 (DE-576)014410524 |
| title |
Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions |
| ctrlnum |
(DE-627)OLC1981412697 (DE-599)GBVOLC1981412697 (PRQ)c1252-84ec96a94320e494dbafe52275f7b82e289e807aec42a24440a05a08ad580d830 (KEY)0026188220160000089106500000lowdoseratebrachytherapyldrbtasmonotherapyforearly |
| title_full |
Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions |
| author_sort |
Fellin, Giovanni |
| journal |
The British journal of radiology |
| journalStr |
The British journal of radiology |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
txt |
| author_browse |
Fellin, Giovanni |
| container_volume |
89 |
| class |
610 DNB XA 34700 AVZ rvk 44.64 bkl 44.40 bkl |
| format_se |
Aufsätze |
| author-letter |
Fellin, Giovanni |
| doi_str_mv |
10.1259/bjr.20150981 |
| dewey-full |
610 |
| title_sort |
low dose rate brachytherapy (ldr-bt) as monotherapy for early stage prostate cancer in italy: practice and outcome analysis in a series of 2237 patients from 11 institutions |
| title_auth |
Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions |
| abstract |
Low-dose-rate brachytherapy (LDR-BT) in localized prostate cancer is available since 15 years in Italy. We realized the first national multicentre and multidisciplinary data collection to evaluate LDR-BT practice, given as monotherapy, and outcome in terms of biochemical failure. Between May 1998 and December 2011, 2237 patients with early-stage prostate cancer from 11 Italian community and academic hospitals were treated with iodine-125 ((125)I) or palladium-103 LDR-BT as monotherapy and followed up for at least 2 years. (125)I seeds were implanted in 97.7% of the patients: the mean dose received by 90% of target volume was 145 Gy; the mean target volume receiving 100% of prescribed dose (V100) was 91.1%. Biochemical failure-free survival (BFFS), disease-specific survival (DSS) and overall survival (OS) were estimated using Kaplan-Meier method. Log-rank test and multivariable Cox regression were used to evaluate the relationship of covariates with outcomes. Median follow-up time was 65 months. 5- and 7-year DSS, OS and BFFS were 99 and 98%, 94 and 89%, and 92 and 88%, respectively. At multivariate analysis, the National Comprehensive Cancer Network score (p < 0.0001) and V100 (p = 0.09) were correlated with BFFS, with V100 effect significantly different between patients at low risk and those at intermediate/high risk (p = 0.04). Short follow-up and lack of toxicity data represent the main limitations for a global evaluation of LDR-BT. This first multicentre Italian report confirms LDR-BT as an excellent curative modality for low-/intermediate-risk prostate cancer. Multidisciplinary teams may help to select adequately patients to be treated with brachytherapy, with a direct impact on the implant quality and, possibly, on outcome. |
| abstractGer |
Low-dose-rate brachytherapy (LDR-BT) in localized prostate cancer is available since 15 years in Italy. We realized the first national multicentre and multidisciplinary data collection to evaluate LDR-BT practice, given as monotherapy, and outcome in terms of biochemical failure. Between May 1998 and December 2011, 2237 patients with early-stage prostate cancer from 11 Italian community and academic hospitals were treated with iodine-125 ((125)I) or palladium-103 LDR-BT as monotherapy and followed up for at least 2 years. (125)I seeds were implanted in 97.7% of the patients: the mean dose received by 90% of target volume was 145 Gy; the mean target volume receiving 100% of prescribed dose (V100) was 91.1%. Biochemical failure-free survival (BFFS), disease-specific survival (DSS) and overall survival (OS) were estimated using Kaplan-Meier method. Log-rank test and multivariable Cox regression were used to evaluate the relationship of covariates with outcomes. Median follow-up time was 65 months. 5- and 7-year DSS, OS and BFFS were 99 and 98%, 94 and 89%, and 92 and 88%, respectively. At multivariate analysis, the National Comprehensive Cancer Network score (p < 0.0001) and V100 (p = 0.09) were correlated with BFFS, with V100 effect significantly different between patients at low risk and those at intermediate/high risk (p = 0.04). Short follow-up and lack of toxicity data represent the main limitations for a global evaluation of LDR-BT. This first multicentre Italian report confirms LDR-BT as an excellent curative modality for low-/intermediate-risk prostate cancer. Multidisciplinary teams may help to select adequately patients to be treated with brachytherapy, with a direct impact on the implant quality and, possibly, on outcome. |
| abstract_unstemmed |
Low-dose-rate brachytherapy (LDR-BT) in localized prostate cancer is available since 15 years in Italy. We realized the first national multicentre and multidisciplinary data collection to evaluate LDR-BT practice, given as monotherapy, and outcome in terms of biochemical failure. Between May 1998 and December 2011, 2237 patients with early-stage prostate cancer from 11 Italian community and academic hospitals were treated with iodine-125 ((125)I) or palladium-103 LDR-BT as monotherapy and followed up for at least 2 years. (125)I seeds were implanted in 97.7% of the patients: the mean dose received by 90% of target volume was 145 Gy; the mean target volume receiving 100% of prescribed dose (V100) was 91.1%. Biochemical failure-free survival (BFFS), disease-specific survival (DSS) and overall survival (OS) were estimated using Kaplan-Meier method. Log-rank test and multivariable Cox regression were used to evaluate the relationship of covariates with outcomes. Median follow-up time was 65 months. 5- and 7-year DSS, OS and BFFS were 99 and 98%, 94 and 89%, and 92 and 88%, respectively. At multivariate analysis, the National Comprehensive Cancer Network score (p < 0.0001) and V100 (p = 0.09) were correlated with BFFS, with V100 effect significantly different between patients at low risk and those at intermediate/high risk (p = 0.04). Short follow-up and lack of toxicity data represent the main limitations for a global evaluation of LDR-BT. This first multicentre Italian report confirms LDR-BT as an excellent curative modality for low-/intermediate-risk prostate cancer. Multidisciplinary teams may help to select adequately patients to be treated with brachytherapy, with a direct impact on the implant quality and, possibly, on outcome. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-PHY SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_24 GBV_ILN_170 GBV_ILN_4012 GBV_ILN_4219 GBV_ILN_4305 |
| container_issue |
1065 |
| title_short |
Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions |
| url |
http://dx.doi.org/10.1259/bjr.20150981 http://www.ncbi.nlm.nih.gov/pubmed/27384381 |
| remote_bool |
false |
| author2 |
Mirri, Maria A Santoro, Luigi Jereczek-Fossa, Barbara A Divan, Claudio Mussari, Salvatore Ziglio, Francesco La Face, Beniamino Barbera, Fernando Buglione, Michela Bandera, Laura Ghedi, Barbara Di Muzio, Nadia G Losa, Andrea Mangili, Paola Nava, Luciano Chiarlone, Renato Ciscognetti, Nunzia Gastaldi, Emilio Cattani, Federica Spoto, Ruggero Vavassori, Andrea Giglioli, Francesca R Guarneri, Alessia Cerboneschi, Valentina Mignogna, Marcello Paoluzzi, Mauro Ravaglia, Valentina Chiumento, Costanza Clemente, Stefania Fusco, Vincenzo Santini, Roberto Stefanacci, Marco Mangiacotti, Francesco P Martini, Marco Palloni, Tiziana Schinaia, Giuseppe Lazzari, Grazia Silvano, Giovanni Magrini, Stefano Ricardi, Umberto Santoni, Riccardo Orecchia, Roberto |
| author2Str |
Mirri, Maria A Santoro, Luigi Jereczek-Fossa, Barbara A Divan, Claudio Mussari, Salvatore Ziglio, Francesco La Face, Beniamino Barbera, Fernando Buglione, Michela Bandera, Laura Ghedi, Barbara Di Muzio, Nadia G Losa, Andrea Mangili, Paola Nava, Luciano Chiarlone, Renato Ciscognetti, Nunzia Gastaldi, Emilio Cattani, Federica Spoto, Ruggero Vavassori, Andrea Giglioli, Francesca R Guarneri, Alessia Cerboneschi, Valentina Mignogna, Marcello Paoluzzi, Mauro Ravaglia, Valentina Chiumento, Costanza Clemente, Stefania Fusco, Vincenzo Santini, Roberto Stefanacci, Marco Mangiacotti, Francesco P Martini, Marco Palloni, Tiziana Schinaia, Giuseppe Lazzari, Grazia Silvano, Giovanni Magrini, Stefano Ricardi, Umberto Santoni, Riccardo Orecchia, Roberto |
| ppnlink |
129077976 |
| mediatype_str_mv |
n |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1259/bjr.20150981 |
| up_date |
2024-07-04T04:54:11.162Z |
| _version_ |
1803622915678142464 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a2200265 4500</leader><controlfield tag="001">OLC1981412697</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230509072502.0</controlfield><controlfield tag="007">tu</controlfield><controlfield tag="008">161013s2016 xx ||||| 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1259/bjr.20150981</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">PQ20161012</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)OLC1981412697</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)GBVOLC1981412697</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(PRQ)c1252-84ec96a94320e494dbafe52275f7b82e289e807aec42a24440a05a08ad580d830</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(KEY)0026188220160000089106500000lowdoseratebrachytherapyldrbtasmonotherapyforearly</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DNB</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XA 34700</subfield><subfield code="q">AVZ</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.64</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Fellin, Giovanni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">ohne Hilfsmittel zu benutzen</subfield><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Band</subfield><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Low-dose-rate brachytherapy (LDR-BT) in localized prostate cancer is available since 15 years in Italy. We realized the first national multicentre and multidisciplinary data collection to evaluate LDR-BT practice, given as monotherapy, and outcome in terms of biochemical failure. Between May 1998 and December 2011, 2237 patients with early-stage prostate cancer from 11 Italian community and academic hospitals were treated with iodine-125 ((125)I) or palladium-103 LDR-BT as monotherapy and followed up for at least 2 years. (125)I seeds were implanted in 97.7% of the patients: the mean dose received by 90% of target volume was 145 Gy; the mean target volume receiving 100% of prescribed dose (V100) was 91.1%. Biochemical failure-free survival (BFFS), disease-specific survival (DSS) and overall survival (OS) were estimated using Kaplan-Meier method. Log-rank test and multivariable Cox regression were used to evaluate the relationship of covariates with outcomes. Median follow-up time was 65 months. 5- and 7-year DSS, OS and BFFS were 99 and 98%, 94 and 89%, and 92 and 88%, respectively. At multivariate analysis, the National Comprehensive Cancer Network score (p < 0.0001) and V100 (p = 0.09) were correlated with BFFS, with V100 effect significantly different between patients at low risk and those at intermediate/high risk (p = 0.04). Short follow-up and lack of toxicity data represent the main limitations for a global evaluation of LDR-BT. This first multicentre Italian report confirms LDR-BT as an excellent curative modality for low-/intermediate-risk prostate cancer. Multidisciplinary teams may help to select adequately patients to be treated with brachytherapy, with a direct impact on the implant quality and, possibly, on outcome.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mirri, Maria A</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Santoro, Luigi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jereczek-Fossa, Barbara A</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Divan, Claudio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mussari, Salvatore</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ziglio, Francesco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">La Face, Beniamino</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barbera, Fernando</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buglione, Michela</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bandera, Laura</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ghedi, Barbara</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Di Muzio, Nadia G</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Losa, Andrea</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mangili, Paola</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nava, Luciano</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chiarlone, Renato</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ciscognetti, Nunzia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gastaldi, Emilio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cattani, Federica</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Spoto, Ruggero</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vavassori, Andrea</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Giglioli, Francesca R</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guarneri, Alessia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cerboneschi, Valentina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mignogna, Marcello</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Paoluzzi, Mauro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ravaglia, Valentina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chiumento, Costanza</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Clemente, Stefania</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fusco, Vincenzo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Santini, Roberto</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stefanacci, Marco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mangiacotti, Francesco P</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Martini, Marco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Palloni, Tiziana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schinaia, Giuseppe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lazzari, Grazia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Silvano, Giovanni</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Magrini, Stefano</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ricardi, Umberto</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Santoni, Riccardo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Orecchia, Roberto</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The British journal of radiology</subfield><subfield code="d">Oxford : Oxford University Press, 1928</subfield><subfield code="g">89(2016), 1065</subfield><subfield code="w">(DE-627)129077976</subfield><subfield code="w">(DE-600)2982-8</subfield><subfield code="w">(DE-576)014410524</subfield><subfield code="x">0007-1285</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:89</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:1065</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">http://dx.doi.org/10.1259/bjr.20150981</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">http://www.ncbi.nlm.nih.gov/pubmed/27384381</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_OLC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-DE-84</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4219</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="936" ind1="r" ind2="v"><subfield code="a">XA 34700</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.64</subfield><subfield code="q">AVZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">AVZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">89</subfield><subfield code="j">2016</subfield><subfield code="e">1065</subfield></datafield></record></collection>
|
| score |
7.4013023 |